Abstract：
TFIIIB, an RNA polymerase III specific transcription factor has been found to be deregulated in human cancers with much of the research focused on the TBP, BRF1, and BRF2 subunits. To date, the TFIIIB specific subunit BDP1 has not been investigated in ovarian cancer but has previously been shown to be deregulated in neuroblastoma, breast cancer, and Non-Hodgkins lymphoma.
Using in silico analysis of clinically derived platforms, we report a decreased BDP1 expression as a result of deletion in serous ovarian cancer and a correlation with higher and advanced ovarian stages. Further analysis in the context of TP53 mutations, a major contributor to ovarian tumorigenesis, suggests that high BDP1 expression is unfavorable for overall survival and high BDP1 expression occurs in stages 2, 3 and 4 serous ovarian cancer. Additionally, high BDP1 expression is disadvantageous and unfavorable for progression-free survival. Lastly, BDP1 expression significantly decreased in patients treated with first-line chemotherapy, platin and taxane, at twelve-month relapse-free survival.
Taken together with a ROC analysis, the data suggest BDP1 could be of clinical relevance as a predictive biomarker in serous ovarian cancer. Lastly, this study further demonstrates that both the over- and under expression of BDP1 warrants further investigation and suggests BDP1 may exhibit dual function in the context of tumorigenesis.
Using in silico analysis of clinically derived platforms, we report a decreased BDP1 expression as a result of deletion in serous ovarian cancer and a correlation with higher and advanced ovarian stages. Further analysis in the context of TP53 mutations, a major contributor to ovarian tumorigenesis, suggests that high BDP1 expression is unfavorable for overall survival and high BDP1 expression occurs in stages 2, 3 and 4 serous ovarian cancer. Additionally, high BDP1 expression is disadvantageous and unfavorable for progression-free survival. Lastly, BDP1 expression significantly decreased in patients treated with first-line chemotherapy, platin and taxane, at twelve-month relapse-free survival.
Taken together with a ROC analysis, the data suggest BDP1 could be of clinical relevance as a predictive biomarker in serous ovarian cancer. Lastly, this study further demonstrates that both the over- and under expression of BDP1 warrants further investigation and suggests BDP1 may exhibit dual function in the context of tumorigenesis.
摘要：
背景：TFIIIB，已经发现一种RNA聚合酶III特异性转录因子在人类癌症中失调，大部分研究集中在TBP上，BRF1和BRF2亚基。迄今为止,TFIIIB特异性亚基BDP1尚未在卵巢癌中进行研究，但先前已显示在神经母细胞瘤中失调，乳腺癌,和非霍奇金淋巴瘤.
结果：使用临床衍生平台的计算机模拟分析，我们报道了由于浆液性卵巢癌中的缺失而导致的BDP1表达下降，并且与卵巢高发和晚期阶段相关。在TP53突变的背景下进行进一步分析，卵巢肿瘤发生的主要原因，提示高BDP1表达不利于总生存期，高BDP1表达发生在2、3和4期浆液性卵巢癌中。此外,高BDP1表达对无进展生存期不利。最后,在接受一线化疗的患者中，BDP1表达显著下降，铂和紫杉烷，在12个月无复发生存期。
结论：结合ROC分析，数据提示BDP1作为浆液性卵巢癌的预测生物标志物可能具有临床意义.最后,这项研究进一步证明了BDP1的过表达和过表达不足都值得进一步研究，并提示BDP1在肿瘤发生背景下可能表现出双重功能。
结果：使用临床衍生平台的计算机模拟分析，我们报道了由于浆液性卵巢癌中的缺失而导致的BDP1表达下降，并且与卵巢高发和晚期阶段相关。在TP53突变的背景下进行进一步分析，卵巢肿瘤发生的主要原因，提示高BDP1表达不利于总生存期，高BDP1表达发生在2、3和4期浆液性卵巢癌中。此外,高BDP1表达对无进展生存期不利。最后,在接受一线化疗的患者中，BDP1表达显著下降，铂和紫杉烷，在12个月无复发生存期。
结论：结合ROC分析，数据提示BDP1作为浆液性卵巢癌的预测生物标志物可能具有临床意义.最后,这项研究进一步证明了BDP1的过表达和过表达不足都值得进一步研究，并提示BDP1在肿瘤发生背景下可能表现出双重功能。
